EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Minimizing false positives for CTC identification

Adriana Carneiro, Paulina Piairo, Beatriz Matos, Daniela A R Santos, Carlos Palmeira, Lúcio Lara Santos, Luís Lima, Lorena Diéguez

Analytica Chimica Acta · 2024-02 · 1288 · 342165

DOI: 10.1016/j.aca.2023.342165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytica Chimica Acta, 2024-02. Verfasst von Adriana Carneiro und 7 weiteren Autor:innen. Beteiligte Einrichtung: International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga s/n, 4715-330, Braga, Portugal; Experimental Pathology and Therapeutics Gr…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, European Regional Development Fund, Fundación La Caixa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low levels of CD45 and stain non-specifically for cytokeratin, increasing their risk of misclassification as CTCs. There is a clear need to improve CTC detection and enumeration criteria to unequivocally eliminate interfering WBC populations. RESULTS: This study showed that, indeed, some granulocyte subpopulations expressed low levels of CD45 and stained non-specifically for cytokeratin, misidentifying them as CTCs. These same cells, however, strongly expressed CD15, allowing them to be identified as WBCs and excluded from CTC classification. Flow cytometry confirmed the specificity of the CD15 antibody for the granulocyte subpopulation. False positives were considerably reduced from 25 % to 0.2 % by double exclusion, combining a CD15 antibody with a highly specific CD45 antibody. Furthermore, complete elimination of potential false positives was achieved using double exclusion in combination with improved selection of cytokeratin antibody. The study emphasises the importance of a robust exclusion criteria and high antibody specificity in CTC immuno-assays for accurate identification of CTC candidates and thorough exclusion of interfering WBC subpopulations. SIGNIFICANCE: This study demonstrated how misidentifying a granulocyte subpopulation can lead to inaccurate CTC evaluation. However, sensitivity and specificity of CTC identification may be improved by using high-performing antibodies and by including a second exclusion biomarker, in turn, allowing for a more comprehensive clinical application of CTCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeoplastic Cells, CirculatingHumansFlow CytometryKeratins

Stichwörter der Autor:innen

Circulating tumour cellsGranulocytesLiquid biopsyMicrofluidics

Substanzen

Biomarkers, TumorKeratins

Autor:innen und Institutionen

  • International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga s/n, 4715-330, Braga, Portugal; Experimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI IPOP) / RISE @ CI-IPOP (Health R…
  • International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga s/n, 4715-330, Braga, Portugal; RUBYnanomed Lda, Praça Conde de Agrolongo 123, 4700-312, Braga, Portugal. Electronic address: paulina.piairo@inl…
  • International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga s/n, 4715-330, Braga, Portugal; NOVA School of Science and Technology, Caparica, 2829-516, Portugal.
  • Experimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI IPOP) / RISE @ CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Po…
  • International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga s/n, 4715-330, Braga, Portugal; RUBYnanomed Lda, Praça Conde de Agrolongo 123, 4700-312, Braga, Portugal. Electronic address: lorena.dieguez@inl…

Förderung

  • Fundação para a Ciência e a Tecnologia
  • European Regional Development Fund
  • Fundación La Caixa
  • European Commission
  • 'la Caixa' Foundation

Zitieren

APA

Carneiro, A., Piairo, P., Matos, B., Santos, D. A. R., Palmeira, C., Santos, L. L., Lima, L., & Diéguez, L. (2024). Minimizing false positives for CTC identification. Analytica Chimica Acta, 1288, 342165. https://doi.org/10.1016/j.aca.2023.342165

Vancouver

Carneiro A, Piairo P, Matos B, Santos DAR, Palmeira C, Santos LL, et al. Minimizing false positives for CTC identification. Analytica Chimica Acta. 2024;1288:342165. doi:10.1016/j.aca.2023.342165

BibTeX
@article{Carneiro2024,
  author = {Carneiro, Adriana and Piairo, Paulina and Matos, Beatriz and Santos, Daniela A R and Palmeira, Carlos and Santos, Lúcio Lara and Lima, Luís and Diéguez, Lorena},
  title = {Minimizing false positives for CTC identification},
  journal = {Analytica Chimica Acta},
  year = {2024},
  volume = {1288},
  pages = {342165},
  doi = {10.1016/j.aca.2023.342165}
}
Kostenlos starten →